23-G玻璃体手术治疗永存原始玻璃体增生症  

Clinical analysis of 23G micro-invasive vitreous surgery for persistent hyperplasia of primary vitreous

作　　者：冯会芳[1] 刘亚东[1] 罗纳丽 

机构地区：[1]黄河中心医院眼科,郑州450003

出　　处：《中华眼外伤职业眼病杂志》2014年第12期946-948,共3页Chinese Journal of Ocular Trauma and Occupational Eye Disease

摘　　要：目的分析23G微创玻璃体手术治疗永存原始玻璃体增生症的临床效果。方法永存原始玻璃体增生症患儿19名（19眼），应用23G微创玻璃体手术系统行晶状体摘出联合玻璃体切除术，其中15例一期植入人工晶状体。术后随访6—36个月。观察术中、术后并发症，视力恢复及结构恢复情况。结果术中及术后均无明显的并发症；至随访期末，17眼（89．47％）视力有不同程度的提高，19例均获得了一定的视力，未发生因病情发展或因并发症而导致二次手术者。其中视力无变化者2眼，术中检查发现存在视网膜发育异常。结论应用23G微创玻璃体手术治疗永存原始玻璃体增生症是一种安全有效的方法，并发症少，术后反应轻，尽早手术可保护有用视力，防止并发症发生。Objective To analyze the clinical effect of 23G micro-invasive vitreous surgery in treatment of persistent hyperplasia of primary vitreous （PHPV）. Methods A retrospective study of 19 eyes of 19 children with PHPV treated with 23G micro-invasive vitreous surgery, extraction of the crystalline lens combined with vitreetomy included 15 cases with intraocular lens implantation. They were followed up for 6 to 36 months. The intraoperative and postoperative complications and visual acuity were analysed. Results There was no significant intraoperative or postoperative complication at the end of the follow-up. The vision were improved in 17 eyes （89.47%） at varying degrees. All 19 children acquired certain vision. No case needed secondary surgery due to the disease progression or complications. Among them, the visual acuity remained unchanged in 2 cases who had retinal dysplasia discovered during the surgery. Conclusion 23G micro-invasive vitreous surgery for PHPV is a safe and effective method which has few complications and mild postoperative reaction. Early surgery may be useful to protect eyesight and prevent complications.

关 键 词：玻璃体增生症 原始 永存 玻璃体手术 23G 微创 

分 类 号：R776.4[医药卫生—眼科]